Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02449681

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Metastatic Head-and-neck Squamous-cell Carcinoma Clinical Trial

Official title:
A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Clinical Trial Summary

This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Clinical Trial Description

An open label, multi-center Phase 2 study in which the pharmacokinetics, safety, tolerability and efficacy of TH-4000 will be assessed in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Hypoxia PET scans will be obtained in select centers to analyze potential predictors of tumor response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02449681
Study type Interventional
Source Rain Oncology Inc
Contact
Status Terminated
Phase Phase 2
Start date August 2015
Completion date January 31, 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04831320 - Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor Phase 2
Recruiting NCT02119559 - Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma N/A
Recruiting NCT05980000 - Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma Phase 2
Recruiting NCT05047094 - A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC N/A
Recruiting NCT04375384 - Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer Phase 2
Recruiting NCT06064877 - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma Phase 3
Recruiting NCT04454489 - Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Phase 2
Recruiting NCT06239220 - PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC Phase 2
Active, not recruiting NCT04305795 - An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors Phase 1/Phase 2